| Name | Title | Contact Details |
|---|
Interrad Medical is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens® Contact Hearing Solution, which directly vibrates the eardrum with a tiny lens in order to activate the natural hearing process. This revolutionary, nonsurgical hearing solution delivers the broadest bandwidth available today and superior sound quality. The Earlens® Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. We believe that people with hearing loss shouldn`t have to think about their hearing in everyday situations. Earlens was designed specifically to address the sound quality and speech understanding complaints that are common among hearing aid wearers and contribute to non-compliance. We make every Earlens device custom-fit for each patient`s unique anatomy and hearing needs, while offering modern features such as Bluetooth streaming.
Gen X International is a Guilford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Litigation is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.